These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 20587907

  • 1. Role of Ki-67 as a proliferative marker in lesions of thyroid.
    Pujani M, Arora B, Pujani M, Singh SK, Tejwani N.
    Indian J Cancer; 2010; 47(3):304-7. PubMed ID: 20587907
    [Abstract] [Full Text] [Related]

  • 2. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors.
    Erickson LA, Jin L, Wollan PC, Thompson GB, van Heerden J, Lloyd RV.
    Mod Pathol; 1998 Feb; 11(2):169-74. PubMed ID: 9504687
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of MIB-1 immunoreactivity and nucleolar organizer regions in nonneoplastic and neoplastic thyroid lesions.
    Lewy-Trenda I, Bieńkiewicz M.
    Pol J Pathol; 1999 Feb; 50(3):129-38. PubMed ID: 10624114
    [Abstract] [Full Text] [Related]

  • 4. Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms.
    Aron M, Kapila K, Verma K.
    Indian J Pathol Microbiol; 2006 Jul; 49(3):376-80. PubMed ID: 17001889
    [Abstract] [Full Text] [Related]

  • 5. The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor.
    Cui W, Lu X, Zheng S, Ma Y, Liu X, Zhang W.
    Clin Lab; 2012 Jul; 58(5-6):419-26. PubMed ID: 22783570
    [Abstract] [Full Text] [Related]

  • 6. Assessment of cyclin D1 gene expression as a prognostic factor in benign and malignant thyroid lesions.
    Brzeziańska E, Cyniak-Magierska A, Sporny S, Pastuszak-Lewandoska D, Lewiński A.
    Neuro Endocrinol Lett; 2007 Aug; 28(4):341-50. PubMed ID: 17693985
    [Abstract] [Full Text] [Related]

  • 7. Significance of AgNORs and ki-67 proliferative markers in differential diagnosis of thyroid lesions.
    Aiad HA, Bashandy MA, Abdou AG, Zahran AA.
    Pathol Oncol Res; 2013 Apr; 19(2):167-75. PubMed ID: 23055017
    [Abstract] [Full Text] [Related]

  • 8. Usefulness of fine needle aspiration of the thyroid in an endemic goiter region.
    Harach HR.
    Acta Cytol; 1989 Apr; 33(1):31-5. PubMed ID: 2916369
    [Abstract] [Full Text] [Related]

  • 9. The efficacy of the thyroid peroxidase marker for distinguishing follicular thyroid carcinoma from follicular adenoma.
    Savin S, Cvejic D, Isic T, Paunovic I, Tatic S, Havelka M.
    Exp Oncol; 2006 Mar; 28(1):70-4. PubMed ID: 16614712
    [Abstract] [Full Text] [Related]

  • 10. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
    Than TH, Swethadri GK, Wong J, Ahmad T, Jamil D, Maganlal RK, Hamdi MM, Abdullah MS.
    Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527
    [Abstract] [Full Text] [Related]

  • 11. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms.
    Mehrotra P, Okpokam A, Bouhaidar R, Johnson SJ, Wilson JA, Davies BR, Lennard TW.
    Histopathology; 2004 Nov; 45(5):493-500. PubMed ID: 15500653
    [Abstract] [Full Text] [Related]

  • 12. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?
    Pu RT, Yang J, Wasserman PG, Bhuiya T, Griffith KA, Michael CW.
    Diagn Cytopathol; 2006 May; 34(5):330-4. PubMed ID: 16604553
    [Abstract] [Full Text] [Related]

  • 13. Minichromosome maintenance protein 3 is a candidate proliferation marker in papillary thyroid carcinoma.
    Lee YS, Ha SA, Kim HJ, Shin SM, Kim HK, Kim S, Kang CS, Lee KY, Hong OK, Lee SH, Kwon HS, Cha BY, Kim JW.
    Exp Mol Pathol; 2010 Feb; 88(1):138-42. PubMed ID: 19818763
    [Abstract] [Full Text] [Related]

  • 14. Fine-needle aspiration biopsy of Hurthle cell lesions of the thyroid gland: A cytomorphologic study of 139 cases with statistical analysis.
    Elliott DD, Pitman MB, Bloom L, Faquin WC.
    Cancer; 2006 Apr 25; 108(2):102-9. PubMed ID: 16453320
    [Abstract] [Full Text] [Related]

  • 15. [Detection of cytokeratin 19 and thyroperoxidase expressions in the diagnosis of thyroid diseases].
    Yang QX, Shao CK, Feng ZY, Huang BQ, Han AJ, Xiong M, Zhao WL, Wu TT.
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun 25; 25(6):678-81. PubMed ID: 15958307
    [Abstract] [Full Text] [Related]

  • 16. Transcription factor-mediated proliferation and apoptosis in benign and malignant thyroid lesions.
    Letsas KP, Frangou-Lazaridis M, Skyrlas A, Tsatsoulis A, Malamou-Mitsi V.
    Pathol Int; 2005 Nov 25; 55(11):694-702. PubMed ID: 16271081
    [Abstract] [Full Text] [Related]

  • 17. [A comparative study of cytological and histological studies of the thyroid gland].
    Emmrich P, Gauer G, Gauer J, Mättig H, Rosenkranz M.
    Zentralbl Chir; 2001 Apr 25; 126(4):267-72. PubMed ID: 11370387
    [Abstract] [Full Text] [Related]

  • 18. Usefulness of cytokeratin-19, galectin-3, and Hector Battifora mesothelial-1 in the diagnosis of benign and malignant thyroid nodules.
    Cui W, Sang W, Zheng S, Ma Y, Liu X, Zhang W.
    Clin Lab; 2012 Apr 25; 58(7-8):673-80. PubMed ID: 22997967
    [Abstract] [Full Text] [Related]

  • 19. Ki-67 as proliferative marker of thyroid.
    Wiwanitkit V.
    Indian J Cancer; 2011 Apr 25; 48(3):378. PubMed ID: 21921351
    [No Abstract] [Full Text] [Related]

  • 20. In situ detection of hTERT mRNA relates to Ki-67 labeling index in papillary thyroid carcinoma.
    Chou SJ, Chen CM, Harn HJ, Chen CJ, Liu YC.
    J Surg Res; 2001 Jul 25; 99(1):75-83. PubMed ID: 11421607
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.